Holen Sie sich die Stockscreener-App
22.77
0.22%
-0.05
Vorhandelsmarkt:
23.12
0.35
+1.54%
Schlusskurs vom Vortag:
$22.82
Offen:
$22.92
24-Stunden-Volumen:
1.13M
Relative Volume:
0.98
Marktkapitalisierung:
$1.46B
Einnahmen:
$193.35M
Nettoeinkommen (Verlust:
$-177.58M
KGV:
-9.2939
EPS:
-2.45
Netto-Cashflow:
$-172.43M
1W Leistung:
+11.78%
1M Leistung:
+11.29%
6M Leistung:
-6.45%
1J Leistung:
-1.90%
1-Tages-Spanne:
$22.37
$23.20
1-Wochen-Bereich:
$20.54
$23.75
52-Wochen-Spanne:
$16.60
$28.47
Schrodinger Inc Stock (SDGR) Company Profile
Firmenname
Schrodinger Inc
Sektor
Branche
Telefon
503-299-1150
Adresse
1540 BROADWAY, NEW YORK, NY
Vergleichen Sie SDGR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SDGR
Schrodinger Inc
|
22.77 | 1.49B | 193.35M | -177.58M | -172.43M | -2.45 |
|
VEEV
Veeva Systems Inc
|
285.20 | 45.64B | 2.86B | 780.66M | 1.20B | 4.72 |
|
TEM
Tempus Ai Inc
|
61.08 | 9.68B | 803.32M | -709.10M | -212.68M | -7.8003 |
|
HQY
Healthequity Inc
|
97.41 | 8.32B | 1.15B | 96.70M | -161.99M | 1.09 |
|
DOCS
Doximity Inc
|
59.38 | 11.63B | 550.17M | 201.35M | 232.07M | 1.00 |
|
WAY
Waystar Holding Corp
|
36.57 | 6.57B | 906.14M | -52.62M | 89.62M | -0.3621 |
Schrodinger Inc Stock (SDGR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2024-07-02 | Eingeleitet | Leerink Partners | Outperform |
| 2023-12-05 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2023-05-05 | Fortgesetzt | Piper Sandler | Overweight |
| 2022-12-19 | Eingeleitet | Goldman | Neutral |
| 2022-03-01 | Eingeleitet | Citigroup | Buy |
| 2021-11-19 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-11-19 | Eingeleitet | Piper Sandler | Overweight |
| 2021-11-11 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-10-13 | Eingeleitet | Berenberg | Buy |
| 2021-09-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-05-25 | Eingeleitet | Craig Hallum | Buy |
| 2020-11-23 | Hochstufung | BofA Securities | Neutral → Buy |
| 2020-10-12 | Hochstufung | Jefferies | Hold → Buy |
| 2020-03-02 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-03-02 | Eingeleitet | Jefferies | Hold |
| 2020-03-02 | Eingeleitet | Morgan Stanley | Equal-Weight |
Alle ansehen
Schrodinger Inc Aktie (SDGR) Neueste Nachrichten
Schrödinger Inc. Stock Analysis and ForecastFree Stock Selection - jammulinksnews.com
What analysts say about Schrödinger Inc. stockSuperior stock growth - jammulinksnews.com
What drives Schrödinger Inc. stock priceStrong return on assets - jammulinksnews.com
Is Schrödinger Inc. a good long term investmentFree Wealth Planning Blueprint - Autocar Professional
Material Informatics Company Evaluation Report 2025 | Schrodinger, Dassault Systèmes, and Citrine Informatics Drive Market Growth Through AI, Simulation, and Collaboration - Yahoo Finance
When the Price of (SDGR) Talks, People Listen - news.stocktradersdaily.com
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Schrodinger stock maintains Buy rating at Citi on Ajax collaboration By Investing.com - Investing.com Canada
Schrodinger stock maintains Buy rating at Citi on Ajax collaboration - Investing.com
Ajax Therapeutics and Schrödinger expand JAK inhibitor collaboration - Investing.com
Ajax Therapeutics and Schrödinger Expand Research Collaboration to Include Additional JAK Target - Business Wire
Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth? - Barchart.com
What makes Schrödinger Inc. stock price move sharplyMoney Making Low Risk Plans - beatles.ru
Morgan Stanley Assumes Coverage on Schrödinger (SDGR) Stock - MSN
BMO Capital Remains a Buy on Schrodinger (SDGR) - The Globe and Mail
(SDGR) On The My Stocks Page - news.stocktradersdaily.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc.SDGR - FinancialContent
Schrödinger (SDGR) Receives FDA Fast Track Designation for Cancer Drug SGR-1505 - MSN
Schrodinger stock rating assumed by Morgan Stanley at Equalweight - Investing.com India
Schrödinger Demonstrates Corporate Sustainability Progress in 2024 Report - ReportAlert
Schrödinger gets Fast Track status for SGR-1505 - MSN
Schrödinger (SDGR) Gains FDA Fast Track for MALT1 Inhibitor - GuruFocus
Schrödinger Receives Fast Track Designation for SGR-1505 for the Treatment of Relapsed/Refractory Waldenström Macroglobulinemia | SDGR Stock News - GuruFocus
Schrödinger gets Fast Track status for SGR-1505 (SDGR:NASDAQ) - Seeking Alpha
Schrodinger Announces Board Elections and Approvals - TipRanks
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger - Bluefield Daily Telegraph
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | SDGR Stock News - GuruFocus
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | PRN_FinancialWrapper | PR Newswire - FinancialContent
Where are the Opportunities in (SDGR) - news.stocktradersdaily.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, ... - Eagle-Tribune
Harbor Capital Advisors Inc. Grows Stake in Schrödinger, Inc. (NASDAQ:SDGR) - Defense World
Schrödinger slides after early-stage trial data for cancer therapy - MSN
Schrödinger: Assessing The Signal And The Noise In The Phase 1 Results - Seeking Alpha
Schrödinger (SDGR) Shares Dip After Initial Phase 1 Trial Data - GuruFocus
Schrödinger Reports Encouraging Initial Phase 1 Clinical Data fo - GuruFocus
Schrodinger Reports 22% Response Rate in Phase 1 Trial of SGR-1505 for B-Cell Cancers; Shares Fall - MarketScreener
Finanzdaten der Schrodinger Inc-Aktie (SDGR)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.73%
0.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):